

Remarks

Claims 1-12 are pending in the instant application. Applicants have amended claims 1-12 to more fully conform with U.S. practice and to remove multiple dependencies. The amendments do not constitute new matter.


The enclosed substitute specification in compliance with 37 CFR 1.121(b)(3) and 1.125 is for publication purposes and does not contain any markings. It includes a new first paragraph cross referencing the related priority applications.

Applicants provide herewith copies of the published international application, the International Search Report and the Written Opinion of the International Preliminary Examining Authority. Also enclosed is the Form PTO-1449 listing the cited references with copies of the non-US citations.

Enclosed are copies of the signed 371 National Phase Power of Attorney and Declaration, which were both executed at the international stage. Applicants also enclose herewith a Petition to Accept Color Drawings with three sets of color figures and the required petition fee.

Applicants believe that the claims, as amended, are in allowable form and earnestly solicited the allowance of claims 1-12.

Respectfully submitted,


Yonggang Ji
Registration No.: 53,073
Agent for Applicants

Customer No.: 22840
GE Healthcare Bio-Sciences Corp.
Patent Department
800 Centennial Avenue
Piscataway, New Jersey 08855-1327
Tel: (732) 980-2875
Fax: (732) 457-8463